Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Sun Pharma To Release...

    Sun Pharma To Release Salary To Ex-Ranbaxy Representatives Using Company App

    Written by savita thakur thakur Published On 13 Oct 2016 6:02 AM  |  Updated On 13 Oct 2016 6:02 AM
    Sun Pharma To Release Salary To Ex-Ranbaxy Representatives Using Company App

    New Delhi : Backed by a Bombay High Court order, drug major Sun Pharmaceutical Industries said it will release salaries of the erstwhile Ranbaxy medical representatives only if they used a company provided software application to report daily activity reports.


    A section of ex-Ranbaxy medical representatives (MRs) had challenged in the industrial court in Mumbai Sun Pharma's move to do away with a software application used by erstwhile Ranbaxy MRs for reporting daily activity reports (DAR) and asked them to switch over to a system provided by it.


    The industrial court had granted an interim order in favour of the MRs. It was challenged by the company in the Bombay High Court.


    The court "has granted the company's request for using the Target Application as the platform for DAR and passed an order in which it has directed the said MRs to start reporting on the Target Application retrospectively", Sun Pharma said in a BSE filing.


    "We have stated very clearly in the court that the company will release the salaries provided these medical representatives (MRs) submit their daily activity reports (DAR) using Target Application," it added.


    As on today the migration of all MRs of the erstwhile Ranbaxy to Target Application has been completed and around 94 per cent of them are reporting on it. The balance 6 per cent are refusing to submit their DAR on Target Application, Sun Pharma said.


    As part of the integration of erstwhile Ranbaxy in Sun Pharma it was decided to use Target Application as a single platform for DAR for the India field force, it added.

    daily activity reportDARmedical representativesRanbaxySun PharmaTarget Application
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok